Symbols / TRIB
TRIB Chart
About
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to aggressive forms of the disease. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 13.90M |
| Enterprise Value | 395.70M | Income | -36.28M | Sales | 48.57M |
| Book/sh | -2.93 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 401 | IPO | — |
| P/E | — | Forward P/E | -0.72 | PEG | — |
| P/S | 0.29 | P/B | -0.25 | P/C | — |
| EV/EBITDA | -28.21 | EV/Sales | 8.15 | Quick Ratio | 0.47 |
| Current Ratio | 1.03 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.60 | EPS next Y | -1.03 | EPS Growth | — |
| Revenue Growth | -5.50% | Earnings | 2025-07-01 09:00 | ROA | -9.46% |
| ROE | — | ROIC | — | Gross Margin | 36.78% |
| Oper. Margin | -3.56% | Profit Margin | -75.88% | Shs Outstand | 18.71M |
| Shs Float | 315.34M | Short Float | 2.46% | Short Ratio | 0.67 |
| Short Interest | — | 52W High | 3.44 | 52W Low | 0.48 |
| Beta | 0.60 | Avg Volume | 3.30M | Volume | 350.98K |
| Target Price | — | Recom | None | Prev Close | $0.75 |
| Price | $0.74 | Change | -0.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.75
Latest analyst target
3. DCF / Fair value
$-7.01
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.75
Low
—
High
—
Mean
—
- Order for 9M rapid HIV tests signals rebound in global screening efforts - Stock Titan ue, 23 Dec 2025 08
- Trinity Biotech plc (TRIB) Releases Q2 2025 Earnings: Revenue Decline and Wider Net Loss - Quiver Quantitative ue, 23 Dec 2025 08
- Trinity Biotech Warned by Nasdaq Over Minimum Public Float Value - TipRanks Fri, 20 Feb 2026 22
- Trinity Biotech (NASDAQ:TRIB) investor five-year losses grow to 85% - Yahoo Finance Wed, 27 Aug 2025 07
- Texas stock exchange gets federal approval as state tries to compete with New York heavyweights - The Texas Tribune Mon, 06 Oct 2025 07
- Trinity Biotech stock soars after NY regulatory approval for preeclampsia test - Investing.com hu, 14 Aug 2025 07
- Why Did Trinity Biotech Stock Surge Nearly 50% In Premarket Today? - Stocktwits ue, 23 Dec 2025 08
- Trinity Biotech’s Premier Hb9210 Wins Sole IFCC Gold HbA1c Classification for 2026 - The Globe and Mail Sat, 14 Feb 2026 08
- Trinity Biotech plc (NASDAQ:TRIB) Held Back By Insufficient Growth Even After Shares Climb 54% - simplywall.st Wed, 24 Dec 2025 08
- New approval lets Trinity Biotech shift HIV test making offshore - Stock Titan ue, 10 Feb 2026 08
- Trinity Biotech Receives Notice of Non-Compliance from Nasdaq Regarding Minimum Bid Price Requirement - Quiver Quantitative Fri, 13 Feb 2026 22
- Trinity Biotech (Nasdaq: TRIB) expands HbA1c column rollout after new clearances - Stock Titan Mon, 15 Dec 2025 08
- Trinity Biotech plc Regains Compliance with Nasdaq Minimum Bid Price and Market Value Requirements - Quiver Quantitative ue, 02 Sep 2025 07
- Diabetes tech firm secures fresh funding and more time to cut debt - Stock Titan ue, 23 Dec 2025 08
- Trinity Biotech (NASDAQ: TRIB) cites Perceptive indication for debt-to-equity conversion - Stock Titan Mon, 27 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -486.75K | -19.19K | -84.05K | -96.92K |
| TaxRateForCalcs | 0.12 | 0.00 | 0.00 | 0.04 |
| NormalizedEBITDA | -13.01M | -12.99M | -10.95M | 8.79M |
| TotalUnusualItems | -3.89M | -12.01M | -18.97M | -2.52M |
| TotalUnusualItemsExcludingGoodwill | -3.89M | -12.01M | -18.97M | -2.52M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -31.22M | -36.87M | -43.59M | -1.85M |
| ReconciledDepreciation | 1.86M | 1.78M | 2.33M | 2.74M |
| ReconciledCostOfRevenue | 40.11M | 37.38M | 45.25M | 47.70M |
| EBITDA | -16.91M | -25.00M | -29.91M | 6.27M |
| EBIT | -18.77M | -26.78M | -32.25M | 3.52M |
| NetInterestIncome | -13.13M | -8.98M | -11.30M | -5.86M |
| InterestExpense | 11.96M | 10.15M | 11.53M | 5.45M |
| InterestIncome | 0.00 | 1.17M | 303.00K | 3.00K |
| NormalizedIncome | -27.81M | -24.88M | -24.70M | 573.08K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -31.79M | -24.02M | -41.01M | 875.00K |
| TotalExpenses | 77.05M | 72.78M | 76.03M | 74.69M |
| TotalOperatingIncomeAsReported | -21.16M | -27.05M | -19.35M | 3.94M |
| DilutedAverageShares | 20.20M | 8.90M | 6.75M | 5.33M |
| BasicAverageShares | 17.96M | 7.65M | 6.75M | 4.18M |
| DilutedEPS | -1.80 | -3.20 | -6.08 | 0.20 |
| BasicEPS | -1.80 | -3.20 | -6.08 | 0.20 |
| DilutedNIAvailtoComStockholders | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeCommonStockholders | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncome | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeIncludingNoncontrollingInterests | -31.79M | -24.02M | -41.01M | 875.00K |
| NetIncomeDiscontinuousOperations | -573.00K | 12.85M | 2.58M | 2.73M |
| NetIncomeContinuousOperations | -31.22M | -36.87M | -43.59M | -1.85M |
| TaxProvision | 486.00K | -59.00K | -194.00K | -74.00K |
| PretaxIncome | -30.73M | -36.93M | -43.78M | -1.92M |
| OtherIncomeExpense | -3.89M | -12.01M | -18.96M | -2.52M |
| OtherNonOperatingIncomeExpenses | 3.00K | 3.00K | 4.00K | |
| SpecialIncomeCharges | -3.89M | -12.01M | -9.29M | -2.52M |
| GainOnSaleOfBusiness | 0.00 | |||
| OtherSpecialCharges | -1.70M | 905.00K | 3.45M | -4.42M |
| WriteOff | -800.00K | 1.50M | 482.00K | 583.00K |
| ImpairmentOfCapitalAssets | 2.21M | 9.61M | 5.36M | 6.36M |
| RestructuringAndMergernAcquisition | 4.18M | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | -9.68M | |||
| NetNonOperatingInterestIncomeExpense | -13.13M | -8.98M | -11.30M | -5.86M |
| TotalOtherFinanceCost | 1.17M | -1.17M | 74.00K | 418.00K |
| InterestExpenseNonOperating | 11.96M | 10.15M | 11.53M | 5.45M |
| InterestIncomeNonOperating | 0.00 | 1.17M | 303.00K | 3.00K |
| OperatingIncome | -15.49M | -15.94M | -13.51M | 6.45M |
| OperatingExpense | 36.93M | 35.39M | 30.78M | 27.00M |
| OtherOperatingExpenses | 3.57M | -138.00K | -340.00K | -4.67M |
| ResearchAndDevelopment | 4.54M | 4.38M | 4.14M | 4.50M |
| SellingGeneralAndAdministration | 28.82M | 31.15M | 26.98M | 22.50M |
| GeneralAndAdministrativeExpense | 24.68M | |||
| OtherGandA | 24.68M | |||
| GrossProfit | 21.44M | 19.45M | 17.27M | 33.45M |
| CostOfRevenue | 40.11M | 37.38M | 45.25M | 47.70M |
| TotalRevenue | 61.55M | 56.83M | 62.52M | 81.15M |
| OperatingRevenue | 61.55M | 56.83M | 62.52M | 81.15M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 12.56M | 12.56M | 12.56M | 12.56M |
| OrdinarySharesNumber | 359.19M | 153.31M | 152.43M | 83.61M |
| ShareIssued | 371.75M | 165.87M | 164.99M | 96.16M |
| NetDebt | 82.83M | 51.17M | 51.68M | 57.40M |
| TotalDebt | 100.76M | 67.43M | 72.20M | 99.16M |
| TangibleBookValue | -86.52M | -40.22M | -37.45M | -36.30M |
| InvestedCapital | 52.82M | 30.91M | 56.08M | 82.99M |
| WorkingCapital | 9.03M | 24.01M | 29.33M | -27.80M |
| NetTangibleAssets | -86.52M | -40.22M | -37.45M | -36.30M |
| CapitalLeaseObligations | 12.76M | 12.57M | 13.94M | 15.85M |
| CommonStockEquity | -35.18M | -23.95M | -2.18M | -319.00K |
| TotalCapitalization | 52.61M | 30.70M | 55.87M | -319.00K |
| TotalEquityGrossMinorityInterest | -35.18M | -23.95M | -2.18M | -319.00K |
| StockholdersEquity | -35.18M | -23.95M | -2.18M | -319.00K |
| OtherEquityInterest | 6.71M | 6.71M | 6.71M | |
| GainsLossesNotAffectingRetainedEarnings | -5.44M | -5.68M | -5.69M | -5.36M |
| OtherEquityAdjustments | 23.00K | 23.00K | 86.00K | 23.00K |
| ForeignCurrencyTranslationAdjustments | -5.46M | -5.71M | -5.78M | -5.38M |
| TreasuryStock | 24.92M | 24.92M | 24.92M | 24.92M |
| RetainedEarnings | -79.12M | -48.64M | -26.70M | 12.56M |
| AdditionalPaidInCapital | 63.40M | 46.62M | 46.46M | 16.19M |
| CapitalStock | 4.19M | 1.97M | 1.96M | 1.21M |
| CommonStock | 4.19M | 1.97M | 1.96M | 1.21M |
| TotalLiabilitiesNetMinorityInterest | 138.47M | 83.38M | 94.28M | 119.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 106.38M | 68.35M | 76.94M | 18.72M |
| OtherNonCurrentLiabilities | 1.81M | |||
| DerivativeProductLiabilities | 1.66M | 526.00K | 1.57M | 0.00 |
| NonCurrentDeferredLiabilities | 4.56M | 2.30M | 5.06M | 4.86M |
| NonCurrentDeferredTaxesLiabilities | 4.56M | 2.30M | 5.06M | 4.86M |
| LongTermDebtAndCapitalLeaseObligation | 98.27M | 65.52M | 70.31M | 13.87M |
| LongTermCapitalLeaseObligation | 10.48M | 10.87M | 12.27M | 13.87M |
| LongTermDebt | 87.79M | 54.65M | 58.05M | |
| LongTermProvisions | 75.00K | |||
| CurrentLiabilities | 32.09M | 15.04M | 17.34M | 100.49M |
| CurrentDeferredLiabilities | 197.00K | 50.00K | 114.00K | 210.00K |
| CurrentDeferredRevenue | 197.00K | 50.00K | 114.00K | 141.00K |
| CurrentDebtAndCapitalLeaseObligation | 2.50M | 1.90M | 1.89M | 85.29M |
| CurrentCapitalLeaseObligation | 2.29M | 1.69M | 1.68M | 1.98M |
| CurrentDebt | 210.00K | 210.00K | 210.00K | 83.31M |
| OtherCurrentBorrowings | 210.00K | 83.31M | ||
| CurrentNotesPayable | 210.00K | 210.00K | 210.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 112.00K | 110.00K | 103.00K | 130.00K |
| CurrentProvisions | 2.45M | 50.00K | 50.00K | 50.00K |
| PayablesAndAccruedExpenses | 26.84M | 12.92M | 15.19M | 14.81M |
| CurrentAccruedExpenses | 13.60M | 7.55M | 8.59M | 7.59M |
| Payables | 13.24M | 5.37M | 6.60M | 7.21M |
| OtherPayable | 5.38M | 800.00K | 31.00K | |
| TotalTaxPayable | 1.02M | 684.00K | 396.00K | 420.00K |
| IncomeTaxPayable | 364.00K | 279.00K | 28.00K | 22.00K |
| AccountsPayable | 6.83M | 3.88M | 6.21M | 6.76M |
| TotalAssets | 103.29M | 59.44M | 92.10M | 118.89M |
| TotalNonCurrentAssets | 62.17M | 20.39M | 45.44M | 46.21M |
| OtherNonCurrentAssets | 28.00K | 43.00K | 55.00K | 56.00K |
| NonCurrentDeferredAssets | 3.55M | 1.98M | 4.22M | 4.10M |
| NonCurrentDeferredTaxesAssets | 3.55M | 1.98M | 4.22M | 4.10M |
| NonCurrentAccountsReceivable | 36.00K | 84.00K | 151.00K | |
| FinancialAssets | 166.00K | 178.00K | 128.00K | 0.00 |
| InvestmentsAndAdvances | 2.46M | 0.00 | ||
| InvestmentinFinancialAssets | 2.46M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 51.34M | 16.27M | 35.27M | 35.98M |
| OtherIntangibleAssets | 37.50M | 16.27M | 22.73M | 23.44M |
| Goodwill | 13.84M | 0.00 | 12.54M | 12.54M |
| NetPPE | 4.62M | 1.89M | 5.68M | 5.92M |
| AccumulatedDepreciation | -66.00M | -64.18M | -59.92M | -57.55M |
| GrossPPE | 70.62M | 66.07M | 65.61M | 63.46M |
| Leases | 2.81M | 2.76M | 2.70M | 2.59M |
| MachineryFurnitureEquipment | 41.03M | 39.04M | 38.22M | 36.54M |
| LandAndImprovements | 26.78M | 24.27M | 24.68M | 24.33M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.12M | 39.04M | 46.67M | 72.69M |
| OtherCurrentAssets | 1.00K | |||
| PrepaidAssets | 1.98M | 2.04M | 1.93M | 1.95M |
| Inventory | 19.37M | 19.93M | 22.50M | 29.12M |
| FinishedGoods | 4.35M | 5.38M | 6.46M | 9.93M |
| WorkInProcess | 4.99M | 4.50M | 3.95M | 5.55M |
| RawMaterials | 10.03M | 10.05M | 12.09M | 13.65M |
| Receivables | 14.60M | 13.38M | 15.65M | 15.71M |
| OtherReceivables | 628.00K | 1.12M | 1.16M | 881.00K |
| TaxesReceivable | 560.00K | 1.56M | 1.88M | 1.54M |
| AccountsReceivable | 13.42M | 10.70M | 12.62M | 13.29M |
| AllowanceForDoubtfulAccountsReceivable | -2.29M | -2.32M | -2.69M | -2.99M |
| GrossAccountsReceivable | 15.70M | 13.02M | 15.31M | 16.28M |
| CashCashEquivalentsAndShortTermInvestments | 5.17M | 3.69M | 6.58M | 25.91M |
| CashAndCashEquivalents | 5.17M | 3.69M | 6.58M | 25.91M |
| CashEquivalents | 0.00 | 3.12M | ||
| CashFinancial | 5.17M | 3.69M | 6.58M | 22.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -14.26M | -14.26M | -6.90M | 4.55M |
| RepaymentOfDebt | -2.50M | -12.37M | -124.01M | -2.94M |
| IssuanceOfDebt | 30.18M | 5.00M | 100.02M | 1.76M |
| IssuanceOfCapitalStock | 7.39M | 0.00 | 25.34M | 0.00 |
| CapitalExpenditure | -10.06M | -2.70M | -5.98M | -8.69M |
| EndCashPosition | 5.17M | 3.69M | 6.58M | 25.91M |
| BeginningCashPosition | 3.69M | 6.58M | 25.91M | 27.33M |
| EffectOfExchangeRateChanges | -175.00K | -44.00K | -112.00K | 55.00K |
| ChangesInCash | 1.65M | -2.84M | -19.22M | -1.47M |
| FinancingCashFlow | 28.81M | -16.04M | -12.32M | -6.02M |
| CashFlowFromContinuingFinancingActivities | 28.81M | -16.04M | -12.32M | -6.02M |
| NetOtherFinancingCharges | -1.05M | -5.74M | -848.00K | |
| InterestPaidCFF | -6.25M | -7.62M | -7.92M | -4.00M |
| CashDividendsPaid | 0.00 | 0.00 | 0.00 | 0.00 |
| NetCommonStockIssuance | 7.39M | 0.00 | 25.34M | 0.00 |
| CommonStockIssuance | 7.39M | 0.00 | 25.34M | 0.00 |
| NetIssuancePaymentsOfDebt | 27.67M | -7.37M | -24.00M | -1.18M |
| NetShortTermDebtIssuance | 0.00 | 0.00 | -86.73M | 0.00 |
| ShortTermDebtPayments | 0.00 | 0.00 | -86.73M | 0.00 |
| NetLongTermDebtIssuance | 27.67M | -7.37M | 62.73M | -1.18M |
| LongTermDebtPayments | -2.50M | -12.37M | -37.28M | -2.94M |
| LongTermDebtIssuance | 30.18M | 5.00M | 100.02M | 1.76M |
| InvestingCashFlow | -22.97M | 24.76M | -5.98M | -8.69M |
| CashFlowFromContinuingInvestingActivities | -22.97M | 24.76M | -5.98M | -8.69M |
| NetInvestmentPurchaseAndSale | 0.00 | -700.00K | 0.00 | 0.00 |
| PurchaseOfInvestment | 0.00 | -700.00K | 0.00 | 0.00 |
| NetBusinessPurchaseAndSale | -12.90M | 28.16M | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | 28.16M | 0.00 | 0.00 |
| PurchaseOfBusiness | -12.90M | 0.00 | 0.00 | |
| NetIntangiblesPurchaseAndSale | -9.66M | -1.90M | -4.88M | -6.88M |
| PurchaseOfIntangibles | -9.66M | -1.90M | -4.88M | -6.88M |
| NetPPEPurchaseAndSale | -405.00K | -803.00K | -1.10M | -1.81M |
| PurchaseOfPPE | -405.00K | -803.00K | -1.10M | -1.81M |
| OperatingCashFlow | -4.19M | -11.56M | -921.00K | 13.24M |
| CashFlowFromContinuingOperatingActivities | -4.19M | -11.56M | -921.00K | 13.24M |
| TaxesRefundPaid | 1.01M | 312.00K | -15.00K | 1.62M |
| InterestReceivedCFO | 0.00 | 0.00 | 2.00K | 1.00K |
| InterestPaidCFO | 0.00 | 0.00 | -11.00K | |
| ChangeInWorkingCapital | 6.19M | -402.00K | 5.73M | -172.00K |
| ChangeInOtherWorkingCapital | 2.11M | 2.29M | 7.39M | 5.59M |
| ChangeInPayablesAndAccruedExpense | 8.19M | -2.77M | 181.00K | -7.59M |
| ChangeInPayable | 8.19M | -2.77M | 181.00K | -7.59M |
| ChangeInInventory | -1.74M | -971.00K | -877.00K | -4.41M |
| ChangeInReceivables | -2.37M | 1.05M | -966.00K | 6.24M |
| OtherNonCashItems | 11.27M | 11.64M | 24.71M | 557.00K |
| StockBasedCompensation | 1.32M | 2.07M | 1.75M | 1.10M |
| ProvisionandWriteOffofAssets | 361.00K | 0.00 | 0.00 | |
| AssetImpairmentCharge | 4.09M | 9.61M | 5.84M | 6.94M |
| DeferredTax | 486.00K | -59.00K | -192.00K | -167.00K |
| DeferredIncomeTax | 486.00K | -59.00K | -192.00K | -167.00K |
| DepreciationAmortizationDepletion | 1.86M | 1.78M | 2.33M | 2.74M |
| DepreciationAndAmortization | 1.86M | 1.78M | 2.33M | 2.74M |
| AmortizationCashFlow | 1.19M | 946.00K | 923.00K | 917.00K |
| AmortizationOfIntangibles | 1.19M | 946.00K | 923.00K | 917.00K |
| Depreciation | 675.00K | 831.00K | 1.41M | 1.83M |
| OperatingGainsLosses | 1.01M | -12.48M | -74.00K | -252.00K |
| NetForeignCurrencyExchangeGainLoss | 1.01M | 238.00K | -76.00K | -251.00K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 2.00K | -1.00K |
| GainLossOnSaleOfBusiness | 0.00 | -12.72M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -31.79M | -24.02M | -41.01M | 875.00K |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for TRIB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|